Somatostatin plus Ulinastatin and/or Gabexate for Severe Acute Pancreatitis

doi:10.12114/j.issn.1007-9572.2018.34.016

Abstract

Abstract: Objective　To evaluate the effectiveness of Somatostatin（SM） plus Ulinastatin（US） or/and Gabexate（GB） for the treatment of severe acute pancreatitis（SAP）.Methods　A total of 266 consecutive patients with SAP who received treatment during July 2008 to January 2018 were enrolled.Based on table of random number，they were divided into 4 groups，receiving SM，SM plus GB，SM plus US，SM plus US and GB，respectively.Clinical parameters including abdominal pain and distention relief time，normal autonomous respiration recovery time，normal heart rate recovery time，normal serum amylase recovery time，blood glucose recovery time，white blood count（WBC），C reaction protein（CRP），blood urea nitrogen（BUN），serum creatinine（Scr），hospitalization costs，length of stay（LOS） and cure rate，incidences of adverse reaction and mortality were analyzed.Results　Both SM plus GB，and SM plus US groups needed less time for abdominal pain and distention relief，recovery of normal autonomous respiration，normal heart rate，normal serum amylase and normal blood glucose，and showed decreased WBC and CRP compared with SM group（P<0.05），as did SM plus US and GB group when compared with SM plus GB group or SM plus US group（P<0.05）.SM plus GB，and SM plus US and GB groups also showed decreased BUN in comparison to SM group，as did SM plus US and GB group when compared with SM plus US group（P<0.05）. Compared with SM group，both SM plus US group and SM plus US and GB group had higher hospitalization costs（P<0.05）. SM plus US and GB group had higher hospitalization costs than SM plus US group（P<0.05）. Furthermore，SM plus GB group and SM plus US group had shorter LOS compared with SM　group（P<0.05）. In comparison with SM plus GB group or SM plus US group，the LOS was shorter in the SM plus US and GB group（P<0.05）.　Significant differences in the cure rate，incidence of adverse reactions and mortality were detected by the overall comparison among the four groups（P<0.05）. However，pairwise comparisons did not find obvious differences in the cure rate，incidence of adverse reactions and mortality（P>0.008 3）. Conclusion　SM is effective for SAP.Moreover，the effectiveness will be better if it is used in combination with US or GB，and far better if used in combination with both the two.

Key words: Pancreatitis, Somatostatin, Gabexate, Ulinastatin, Treatment outcome

摘要： 目的　探讨生长抑素（SM）联合乌司他丁（US）和/或加贝酯（GB）治疗重症急性胰腺炎（SAP）的效果。方法　选择2008年7月—2018年1月收治的266例SAP患者，按随机数字表法分为SM、SM+GB、SM+US、SM+US+GB组。比较4组腹胀消失时间、腹痛消失时间、呼吸恢复正常时间、心率恢复正常时间、血清淀粉酶恢复正常时间、血糖恢复正常时间、白细胞计数（WBC）、C反应蛋白（CRP）、血尿素氮（BUN）、血肌酐（Scr）、住院费用、住院时间、治愈率、不良反应发生率及病死率。结果　SM+GB组及SM+US组的腹胀消失时间、腹痛消失时间、呼吸恢复正常时间、心率恢复正常时间、血清淀粉酶恢复正常时间、血糖恢复正常时间、WBC和CRP均低于SM组，差异有统计学意义（P<0.05）；SM+US+GB组的上述参数均低于SM+GB组或SM+US组，差异有统计学意义（P<0.05）。SM+US组及SM+US+GB组的BUN低于SM组，SM+US+GB组低于SM+US组，差异有统计学意义（P<0.05）。SM+US组及SM+US+GB组的住院费用高于SM组，SM+US+GB组高于SM+US组，差异有统计学意义（P<0.05）；SM+GB组及SM+US组的住院时间短于SM组，SM+US+GB组的住院时间短于SM+GB组或SM+US组，差异有统计学意义（P<0.05）；4组治愈率、不良反应发生率、病死率比较，差异有统计学意义（P<0.05），但两两比较，差异无统计学意义（P>0.008 3）。结论　SM能有效治疗SAP，联用US或GB均能提高临床疗效，联用US和GB效果更佳。

关键词: 胰腺炎, 生长抑素, 加贝酯, 乌司他丁, 治疗结果

WANG Guiliang,QIU Ping,XU Linfang, et al. Somatostatin plus Ulinastatin and/or Gabexate for Severe Acute Pancreatitis　[J]. Chinese General Practice, 2018, 21(34): 4241-4245. DOI: 10.12114/j.issn.1007-9572.2018.34.016.
王桂良,邱萍,徐林芳等. 生长抑素联合乌司他丁和/或加贝酯治疗重症急性胰腺炎的临床疗效研究[J]. 中国全科医学, 2018, 21(34): 4241-4245. DOI: 10.12114/j.issn.1007-9572.2018.34.016.

References

［1］汤华，桑卫东.重症急性胰腺炎微创治疗研究进展［J］.安徽医学，2018，46（3）：367-369.DOI：10.3969/j.issn.1000-0399.2018.03.037.
TANG H，SANG W D.Advances in minimally invasive treatment of severe acute pancreatitis［J］.Anhui Medical Journal，2018，46（3）：367-369.DOI：10.3969/j.issn.1000-0399.2018.03.037.
［2］PORTELLI M，JONES C D.Severe acute pancreatitis：pathogenesis，diagnosis and surgical management［J］.Hepatobiliary Pancreat Dis Int，2017，16（2）：155-159.
［3］SHAH A P，MOURAD M M，BRAMHALL S R.Acute pancreatitis：current perspectives on diagnosis and management［J］.J Inflamm Res，2018，11：77-85.DOI：10.2147/JIR.S135751.
［4］SETA T，NOGUCHI Y，SHIKATA S，et al.Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion：an updated systematic review and meta-analysis［J］.BMC Gastroenterol，2014，14：102.DOI：10.1186/1471-230X-14-102.
［5］WANG G，WEN J，WILBUR R R，et al.The effect of Somatostatin，Ulinastatin and Salvia Miltiorrhiza on severe acute pancreatitis treatment［J］.Am J Med Sci，2013，346（5）：371-376.DOI：10.1097/MAJ.
［6］KIM S C，YANG H R.Clinical efficacy of Gabexate Mesilate for acute pancreatitis in children［J］.Eur J Pediatr，2013，172（11）：1483-1490.DOI：10.1007/s00431-013-2068-6.
［7］ABRAHAM P，RODRIQUES J，MOULICK N，et al.Efficacy and safety of intravenous Ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis［J］.J Assoc Physicians India，2013，61（8）：535-538.
［8］中华医学会消化病学分会胰腺疾病学组.中国急性胰腺炎诊治指南（草案）［J］.中华消化杂志，2004，24（3）：190-192.
Pancreatology Group，Chinese Society of Gastroenterology.The Chinese treatment of acute pancreatitis guide（draft）［J］.Chin J Dig，2004，24（3）：190-192.
［9］BOLLEN T L，VAN SANTVOORT H C，BESSELINK M G，et al.The atlanta classification of acute pancreatitis revisited［J］.Br J Surg，2008，95（1）：6-21.
［10］TALUKDAR R，SWAROOP VEGE S.Early management of severe acute pancreatitis［J］.Curr Gastroenterol Rep，2011，13（2）：123-130.DOI：10.1007/s11894-010-0174-4.
［11］HARPER S J，CHESLYN-CURTIS S.Acute pancreatitis［J］.Ann Clin Biochem，2011，48（Pt 1）：23-37.DOI：10.1258/acb.2010.010196.
［12］ZEREM E.Treatment of severe acute pancreatitis and its complications［J］.World J Gastroenterol，2014，20（38）：13879-13892.DOI：10.3748/wjg.v20.i38.13879.
［13］SCHEPERS N J，BESSELINK M G，VAN SANTVOORT H C，et al.Early management of acute pancreatitis［J］.Best Pract Res Clin Gastroenterol，2013，27（5）：727-743.DOI：10.1016/j.bpg.2013.08.007.
［14］JIANG W，YU X，SUN T，et al.Adjunctive Ulinastatin in Sepsis Treatment in China（ADJUST study）：study protocol for a randomized controlled trial［J］.Trials，2018，19（1）：133.DOI：10.1186/s13063-018-2513-y.
［15］INO Y，ARITA Y，AKASHI T，et al.Continuous regional arterial infusion therapy with Gabexate Mesilate for severe acute pancreatitis［J］.World J Gastroenterol，2008，14（41）：6382-6387.
［16］GAO H J，SONG Q，LYU F Q，et al.A novel thermosensitive in-situ gel of Gabexate Mesilate for treatment of traumatic pancreatitis：an experimental study［J］.J Huazhong Univ Sci Technolog Med Sci，2015，35（5）：707-711.DOI：10.1007/s11596-015-1494-2.
［17］HOU J，ZHU M W，HE X W，et al.Effect of hyperbaric oxygen and Ulinastatin on plasma endotoxin，soluble CD14，endotoxin-neutralizing capacity and cytokines in acute necrotizing pancreatitis［J］.Can J Surg，2010，53（4）：241-245.
［18］KARNAD D R，BHADADE R，VERMA P K，et al.Intravenous administration of Ulinastatin（human urinary trypsin inhibitor） in severe sepsis：a multicenter randomized controlled study［J］.Intensive Care Med，2014，40（6）：830-838.DOI：10.1007/s00134-014-3278-8.
［19］ANDRIULLI A，LEANDRO G，CLEMENTE R，et al.Meta-analysis of Somatostatin，Octreotide and Gabexate Mesilate in the therapy of acute pancreatitis［J］.Aliment Pharmacol Ther，1998，12（3）：237-245.
［20］LAGOO J Y，D'SOUZA M C，KARTHA A，et al.Role of Ulinastatin，a trypsin inhibitor，in severe acute pancreatitis in critical care setting：a retrospective analysis［J］.J Crit Care，2018，45：27-32.DOI：10.1016/j.jcrc.2018.01.021.
［21］FENG C，SU X，CHEN L I，et al.Ulinastatin enhances the therapeutic effect of intraperitoneal lavage on severe acute pancreatitis in rats［J］.Exp Ther Med，2015，9（5）：1651-1655.
［22］YASUNAGA H，HORIGUCHI H，HASHIMOTO H，et al.Effect and cost of treatment for acute pancreatitis with or without Gabexate Mesilate：a propensity score analysis using a nationwide administrative database［J］.Pancreas，2013，42：260-264.DOI：10.1097/MPA.0b013e31826495a0.

[1]	WU Xiangpeng, LI Enjun, LI Xiongwei, WANG Haihong, CUI Wei, WU Xiangli, QI Weihua, HOU Senlin. Timing of Administration and Combination Therapy of Non-steroidal Anti-inflammatory Drugs for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis [J]. Chinese General Practice, 2025, 28(30): 3823-3830.
[2]	LUO Xinyu, LIU Jin, CHEN Hailong. Trend Analysis of the Changing Disease Burden of Pancreatitis in China and Worldwide from 1990 to 2021 and Prediction for 2022 to 2031 [J]. Chinese General Practice, 2025, 28(26): 3321-3327.
[3]	MA Panpan, WANG Sijing, YOU Na, DING Dafa, LU Yibing. Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis [J]. Chinese General Practice, 2025, 28(21): 2679-2685.
[4]	GUO Shengteng, ZHANG Fenfen, WAN Di, YU Dongmei, WANG Qinghua. Risk Factors for Severe Acute Pancreatitis Complicated with Acute Lung Injury: a Meta-analysis [J]. Chinese General Practice, 2025, 28(20): 2546-2554.
[5]	ZHU Shengjie, DIAO Huaqiong, HANG Xiaoyi, SUN Wenjun. Network Meta-analysis of Different Traditional Chinese Medicine Injections for the Treatment of Posterior Circulatory Ischemic Vertigo [J]. Chinese General Practice, 2025, 28(14): 1795-1808.
[6]	LIU Caiping, ZHANG Yanhua, TANG Jianpin, WANG Chengpeng, XUE Fengfeng, WANG Huijuan, LI Chuanwei, ZHANG Guangya, LI Huafang. Efficacy and Safety of Long-acting Risperidone Microspheres in the Maintenance Treatment of Schizophrenia [J]. Chinese General Practice, 2025, 28(13): 1622-1627.
[7]	MA Huping, REN Rong, HOU Mei, YUAN Aiyun. Clinical Observation of the New Antiepileptic Drug Perampanel in the Treatment of Refractory Epilepsy in Children Aged 0-18 Years [J]. Chinese General Practice, 2025, 28(02): 250-256.
[8]	YANG Can, LI Ning, LI Xuefei, ZHAO Li, XU Hao, SHI Qi, WANG Yongjun, LIANG Qianqian. Efficacy of Zang Bi Formula in Treating Arthritis and Its Pulmonary Complications in Rheumatoid Arthritis Interstitial Lung Disease Mice [J]. Chinese General Practice, 2024, 27(24): 3015-3022.
[9]	PANG Lan, LI Peifan, ZHU Xiaogang, YANG Zaihong, ZHENG Lei. Deep Transcranial Magnetic Stimulation Combined with Escitalopram Oxalate in the Treatment of Depression: a Randomized Controlled Trial [J]. Chinese General Practice, 2024, 27(17): 2098-2103.
[10]	LI Sisi, HE Qiang, XU Youqing. The Assessment Value of Systemic Inflammation Response Index in Evaluating the Severity of Acute Pancreatitis [J]. Chinese General Practice, 2024, 27(17): 2104-2108.
[11]	ZHAO Yanan, HAN Shifan, LI Ying, ZHOU Liyuan, YANG Jie, WU Jiaxin, CHEN Ganggang. Efficacy of Virtual Reality Vestibular Rehabilitation Training in Patients with Sudden Deafness and Vertigo: a Randomized Controlled Trial [J]. Chinese General Practice, 2024, 27(14): 1672-1677.
[12]	ZHANG Yong, WANG Senli, HUANG Ronghua, XU Fengping, LIU Dan. Intervention Effect of Music Therapy on Patients with Alzheimers Disease: a Meta-analysis [J]. Chinese General Practice, 2024, 27(12): 1511-1518.
[13]	XU Jun, QI Wenjie, WANG Chao, HU Lan, MIAO Bin. Analysis of Clinical Characteristics and Maternal and Neonatal Outcomes in Pregnancy Complicated with Acute Pancreatitis Patients of Different Etiologies [J]. Chinese General Practice, 2024, 27(11): 1343-1348.
[14]	GAO Yuan, ZHOU Min, QIN Manfen, XU Xuan, YANG Liping, FU Yahong, HUANG Ying, WANG Wei. Effects of Health Coaching Combined with Wearable Devices on Glucose and Lipid Metabolism and Self-management Behavior in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2024, 27(08): 908-914.
[15]	ZHENG Rong, LIU Zhidong, WANG Miao, ZHANG Xiao, CHEN Junlan, ZHOU Shigao. A Randomized Controlled Study on Gehu Tiaozhi Decoction Intervening Patients with Metabolic Syndrome [J]. Chinese General Practice, 2024, 27(03): 343-347.